DOCSLIB.ORG

An Annotated Bibliography of the Scientific Literature Referring to Mdma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
An Annotated Bibliography of the Scientific Literature Referring to Mdma AN ANNOTATED BIBLIOGRAPHY OF THE SCIENTIFIC LITERATURE REFERRING TO MDMA (including a sampling of the popular literature) ALEXANDER T. SHULGIN 1483 SHULGIN ROAD LAFAYETTE.CA 94549 JULy 1.1988 2 MDMA BIBLIOGRAPHY TABLE OF CONfENTS (1) Chemistry 3 (2) In Vitro Studies 5 (3) BiochemiStry 7 (4) Phannacology (behavior and drug discrimination studies) 9 (5) Neurochemistry 15 (6) Toxicology 23 (7) Clinical Studies 27 (8) Analysis 31 (9) Reviews and Commentaries (including books and magazine articles) 35 (10) Legal History 47 SECTION 1: CHEMISTRY 3 (1) CHEMISTRY Anon: Verlahren rur Darstellung von Alkyloxyaryl-. Dialkyloxyaryl- und Alkylendioxyarylamino­ propanen bzw. deren am SHckstoif monoalkylierten Derivaten. German Patent. 274.350; Filed December 24. 1912. issued May 16. 1914. Assigned to E. Merck in Dannstadt. A chemical process is described for the conversion of several allyl- and propenyl­ aromatic compounds to the corresponding beta- or alpha-bromopropanes. These. in tum. react with ammonia or primary arn1nes to produce the corresponding prtmary or secondary propylamines. Specifically. safrole was reacted with aqueous HBr. and the impure reaction product reacted with alcoholic methylamine to produce MDMA in an unstated yield. Also described and characterized are MDA and DMA. as well as the corresponding 1-phenyl-1­ aminopropanes. No pharmacology. Anon: Fonnyl Derivatives of Secondary Bases. German Patent 334.555. assigned to E. Merck 1920. CA: 17: 1804a. A chemical conversion ofMDMA to its fonnyl derivative. and the properties of the latter. are described. Biniecki. S. and Krajewski. E. Preparation of DL-l-(3,4-Methylenedioxy)-2-(methylamino)propane and DL-1-(3.4-dimethoxyphenyl)- 2-(methylamino)propane. Acta Polon. Pharm. 11 pp. 421-425 (1960). CA: (1961) 14350e. A chemical procedure is given for the conversion of safrole to the beta-bromopropane with HEr. and its subsequent conversion with alcoholic methylamine to MDMA. 4-Allylvera­ trole was similarly converted to 3.4-dimethoxy- methamphetamine. Braun. U .. Shulgin. AT. and Braun. G., Centrally Active N- Substituted Analogs of 3.4-Methylene­ dioxyphenyl1sopropylamine (3.4-Methylenedioxyamphetaminel. J. Phann. Sci.. ~ pp 192-195 (1980). Twenty two homologs and analogs of MDA were synthesized and their physical properties presented. Twelve ofthem were assayed in man as psychotomimetic agents. Three of them were found to be active: MDMA with a human potency of between 100 and 160 rug orally; MDE somewhat less potent at a dosage requirement of 140-200 mg orally; and MDOH. which was similar to MDMA in potency. Some animal phannacology is reviewed. and a comparison between MDMA and MDA (toxicology. CNS pharmacology. and human effective­ ness) Is tabulated. FUjisawa. T. and Deguchi. Y. (Concerning the Commercial Utilization ofSafrole). J. Pharm. Soc. Japan 74 975 (1954). CA: ~: 109581. The conversion of safrole to piperonylacetone 15 described, using fonnic acid and hydrogen peroxide. in acetone. The yield is satisfactory. and this is probably the most direct and efikient conversion of a natural product to an immediate precursor to MDMA Janesko, J .L. and Dal Cason. T.A. Seizure of a Clandestine Laboratory: The N-Alkyl MDA Analogs Paper presented at the 39thAImual Meeting of the AmertcanAcademy ofForensic Sciences. San Diego. 4 MDMA BIBLIOGRAPHY CA Feb. 16-21 (1987). See Microgram, 2.Q 52 (1987). Several clandestine laboratortes have been seized. revealing the illicit preparation ofnot only MDMA. but the N-ethyl (MDEJ. the N-propyl (MDPR). the N-isopropyl (MDIP) and the N}'J­ dimethyl (MDDM) homologues. These were all synthesized by the NaCNBH3 reduction method from the appropriate amine salt and piperonylacetone. Also. the N- ethyl-N-methyl, and the N.N-diethyl homologs were found. prepared by catalytic hydrogenation. i'.'ichols. D.E., SyntheSiS of3,4-Methylenedioxymetharnphetamine Hydrochloride. FDA Master File on MDMA 1986. A detailed synthesis of MDMA from piperonylacetone is presented. including all the spectroscopic and physical detail, bibliographies, CVs. and such that define the final product for medical needs. Shulgin. A.T. and Jacob III. P., Potential Misrepresentation of 3,4-Methylenedioxyarnphetamine (MDA). A Toxicological Warning. J. Anal. Tox., 2. pp 71-75 (1982). The commercial availability and overt misrepresentation of3,4-methylenedioxybenzyl­ acetone as 3,4-methylenedioxyphenylacetone might well suggest that an unsuspecting attempt to synthesize MDMA may yield a new and unexplored base. 1-(3,4-methylenedioxy­ phenyl)-3-(methylamino)butane. This compound was synthesized. and characterized in compartson to MDMA. The analogous relationship between MDA and its comparable homolog. 1-(3,4-methylenedioxyphenyI1-3- aminobutane. was also explored. SECTION 2: ~N VI1RO STUDIES 5 (2) IN VI1RO STUDIES Brady. J.F.. Di Stephano. E.W. and Cho. AK.. Spectral and Inhibitory Interactions of (+/-)-3.4­ Methylenedioxyamphetamine (MDA) and (+/-)-3.4-Methylenedioxymethamphetam1ne (MDMA) with Rat Hepatic Microsomes. Life Sciences lli! 1457-1464. Both MDA and MDMA were shown to form complexes with cytochrome P-450 that were inhibitory to its function as to demethylation ofbenzphetam1ne and carbon monoxide bindmg. Liver microsome studies showed the metabolic demethylation ofMDMA and the N-hydroxyla­ tion ofMDA Frye. G. and Matthews. R Effect of 3.4-methylenedioxymethamphetam1ne (MDMA) on Contractive Responses in the G. Pig Ileum. The Pharmacologist 2E 149 (#318) (1986). Using the longitudinal muscle of the guinea pig ilium. MDMA evoked dose-related. transient contractions. but failed to reduce contractions produced by serotonin. acetylcholine. or GABA. The MDMA contractions were blocked by atropine. and do not appear to involve serotonin receptors. Gehlert. D.R. Schmidt. C.J.. Wu. L. and Levenberg. W .. Evidence for Specific Methylenedioxymetham­ phetamine (Ecstasy) Binding Sites in the Rat Brain. Europ. J. Pharmacol.lli 135-136 (1985). Evidence is presented from binding to rat brain homogenate studIes. The use of the serotoninerglc re-uptake inhibitor. active in vivo. does not antagonize this binding. nor in studies with uptake into striatal microsomes. Levin. JA.. Schmidt, C.J. and Levenberg. W. Release of [3H)_ Monoamines from Superfused Rat Striatal Slices by Methylenedioxymethamphetam1ne (MDMA). Fed. Proc. ~ 1059 (#5265) April 13­ 18. 1986. The release oftritiated serotonin and dopamine from superfused rat striatal slices was observed for three amphetamine derivatives. MDMA and p-chloroamphetam1ne were equiva­ lent. and about lOx the potency ofmethamphetam1ne. ThIs last compound was. however. some lOx more effective than MDMA in the relase of dopamine. Lyon. RA.. Glennon. RA. and TIteler, M. 3.4-Methylenedioxymethamphetam1ne (MDMA): Stereo­ selective Interactions at Brain 5- HT) and 5-HT2Receptors. Psychopharmacology.a8 525-526 (1986). Both MDMA and MDA, and their respective opUcalisomers, were assayed as to their affinity at radio-labelled serotonin (5-HT) and 5-HT2) and dopamine (D 2) binding sites. The "R" isomers of both drugs showed a moderate affinity at the 5-HT:z receptor (labelled with 3H ketansertn). and the MS" isomers were lower. Affinities for the 5-HT) site were similar. but that for D2 sites were very low. Since the MS" isomer ofMDMA is the more potent in man. it may not work primarily through a direct interaction at 5-HT receptors. Nichols, D.E., Lloyd. D.H., Hoffman, AJ.• Nichols. M.B. and Yim. G.K.W. Effects of Certain Hallucinogenic Amphetamine Analogues on the Release of PHI Serotonin from Rat Brain Synapto­ somes. J. Med. Chern. ~. pp 530-535 (1982). 6 MDMA BIBLIOGRAPHY The optically active isomers of MDMA (as well as those for MDA. PMA) and the corresponding phenterm1ne analogs, have been evaluated as to their effect on the release of serotonin from rat brain synaptosomes. The (+) isomer of MDMA was the more effective (this is the acUve isomer in humans) suggesting that serotonin release may play some role in the psychopharmacological activity. The alpha-alpha dimethyl homologues were inactive even at the highest concentrations studied. Steele, T.P., Nichols, D.E. and Yim, G.K.W. StereoselecUve Effects of MDMA on Inhibition of Mono­ amine Uptake. Fed. Proc. ~ 1059 (# 5262) April 13-18 1986. In the investigation ofthe opUcalisomeric difference ofactivities seen for amphetamtne, MDMA. and DOM (the more potent isomers being the WS", WS" and WR" resp.) their abilities to inhibit the uptake ofradio-labelled monoamines into synaptosomeswere studied, The findings are discussed, and it is concluded that MDMA exhibits stereoselecUve effects similar to those of amphetamine on monoamine uptake inhibition, a parameter that is unrelated to the mechanism of action of the hallucinogen DOM. Steele, T.D., Nichols, D.E. and Yim. G.K.W. Stereochemical Effects of 3,4-Methylenedioxymetham­ phetamtne (MDMA) and Related Amphetamine Derivatives on Inhibition ofUptake of [3H]Monoamtnes into Synaptosomes from Different Regions of Rat Brain. Biochem. Pharmacol. aG 2297-2303 (1987). MDA. MDMA. and the alpha-ethyl homolog MEDE were found to inhibit serotonin uptake in brain synaptosomes. The conclUSiOns to a broad series of studies were that MDMA and its homologs are more closely related to amphetamine than to DOM in their biochemical actions. Wang, 5.5., Ricaurte, GA. and Peroutka, S.J.. [3Hl 3,4 Methylenedioxymethamphetamtne (MDMA) Interactions with Brain Membranes and Glass Fiber Filter Paper, Europ. J. Pharmacol. .!.J.8 439-443 (1987). Tritiated MDrvIA appears to give a pharmacological
Load more

Recommended publications
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Methylphenidate Versus Dexamphetamine in Children with Attention Deficit Hyperactivity Disorder: a Double-Blind, Crossover Trial
    Methylphenidate Versus Dexamphetamine in Children With Attention Deficit Hyperactivity Disorder: A Double-blind, Crossover Trial Daryl Efron, FRACP; Frederick Jarman, FRACP; and Melinda Barker, Grad Dip Ed Psych ABSTRACT. Objective. To compare methylphenidate behavioral, academic, and social functioning. Many (MPH) and dexamphetamine (DEX) in a sample of chil- well-designed, placebo-controlled studies have dem- dren with attention deficit hyperactivity disorder onstrated beyond doubt the benefits of stimulants in (ADHD). the vast majority of children with ADHD.2–4 In a Method. A total of 125 children with ADHD received review of 110 studies on the effects of stimulant both MPH (0.3 mg/kg twice daily) and DEX (0.15 mg/kg drugs on more than 4200 children with ADHD, twice daily) for 2 weeks a double-blind, crossover study. 4 ; Outcome measures were Conners’ Parent Rating Scale– Barkley found that 75% of subjects were regarded Revised, Conners’ Teacher Rating Scale–Revised, a Par- as improved on stimulants. The mean placebo re- ent Global Perceptions questionnaire, the Continuous sponse was 39%. Performance Test, and the Barkley Side Effects Rating Methylphenidate (MPH) and dexamphetamine Scale. (DEX) are the two stimulants prescribed most fre- Results. There were significant group mean im- quently and have been shown to have similar types provements from baseline score on all measures for of positive effects in children with ADHD. However, both stimulants. On the Conners’ Teacher Rating Scal- it is not known whether one is more efficacious than e–Revised, response was greater on MPH than DEX on the other in terms of probability of producing a the conduct problems and hyperactivity factors, as well positive response, magnitude of response, quality of as on the hyperactivity index.
    [Show full text]
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
    [Show full text]
  • Amphetamine/Dextroamphetamine IR Generic
    GEORGIA MEDICAID FEE-FOR-SERVICE STIMULANT AND RELATED AGENTS PA SUMMARY Preferred Non-Preferred Amphetamine/dextroamphetamine IR generic Adzenys ER (amphetamine ER oral suspension) Armodafinil generic Adzenys XR (amphetamine ER dispersible tab) Atomoxetine generic Amphetamine/dextroamphetamine ER (generic Concerta (methylphenidate ER/SA) Adderall XR) Dextroamphetamine IR tablets generic Aptensio XR (methylphenidate ER) Focalin (dexmethylphenidate) Clonidine ER generic Focalin XR (dexmethylphenidate ER) Cotempla XR (methylphenidate ER disintegrating Guanfacine ER generic tablet) Methylin oral solution (methylphenidate) Daytrana (methylphenidate TD patch) Methylphenidate CD/CR/ER generic by Lannett Desoxyn (methamphetamine) [NDCs 00527-####-##] and Kremers Urban [NDCs Dexmethylphenidate IR generic 62175-####-##] (generic Metadate CD) Dexmethylphenidate ER generic Methylphenidate IR generic Dextroamphetamine ER capsules generic Modafinil generic Dextroamphetamine oral solution generic Quillichew ER (methylphenidate ER chew tabs) Dyanavel XR (amphetamine ER oral suspension) Quillivant XR (methylphenidate ER oral suspension) Evekeo (amphetamine tablets) Vyvanse (lisdexamfetamine) Methamphetamine generic Zenzedi 5 mg, 10 mg IR tablets (dextroamphetamine) Methylphenidate IR chewable tablets generic Methylphenidate ER/SA (generic Concerta) Methylphenidate ER/LA/SR (generic Ritalin LA, Ritalin SR, Metadate ER) Methylphenidate ER/SA 72 mg generic Methylphenidate oral solution generic Mydayis (amphetamine/dextroamphetamine ER) Ritalin LA 10 mg
    [Show full text]
  • (Adhd) Quantity Limitation Utilization Management Criteria
    ATTENTION- DEFICIT HYPERACTIVITY DISORDER (ADHD) QUANTITY LIMITATION UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: Stimulants and Non-Stimulants BRAND (generic) NAMES: Adderall® (amphetamine/dextroamphetamine) Adderall XR® (amphetamine/ dextroamphetamine ER) Adzenys XR-ODTTM (amphetamine ER dispersible) Aptensio XR® (methylphenidate ER) Concerta® (methylphenidate ER) Daytrana® (methylphenidate transdermal patch) Dextroampthetamine (DextroStat®) Dexedrine® (dextroamphetamine ER) DyanavelTM XR (amphetamine ER) Focalin XR® (dexmethylphenidate ER) Focalin® (dexmethylphenidate) Intuniv® (guanfacine ER) Kapvay® (clonidine ER) Metadate CD® (methylphenidate ER) Metadate ER® (methylphenidate ER) Methylin® (methylphenidate) Procentra® (dextroamphetamine) QuillichewTM (methylphenidate ER) Quillivant XR® (methylphenidate ER) Ritalin® (methylphenidate) Ritalin® LA (methylphenidate ER) Ritalin® SR (methylphenidate ER) Strattera® (atomoxetine) Vyvanse® (lisdexamphetamine) Zenzedi® (dextroamphetamine) COVERAGE AUTHORIZATION CRITERIA Non-formulary medications - Medications included in this criterion that are not part of ASO Net Results or Essential Formularies are subject to a trial and failure of up to TWO formulary alternatives that are clinically appropriate, to treat the same condition, prior to approval (see Non-formulary Exception Criteria for detailed limitations). Quantities above the program set limit (see pgs 2-4) for ADHD agents will be approved when the following is met: 1. The quantity (dose) requested is for documented titration purposes at the initiation of therapy (authorization for a 90 day titration period); AND 2. The prescribed dose cannot be achieved using a lesser quantity of a higher strength; AND 3. The quantity (dose) requested does not exceed the maximum FDA labeled dose, when specified, or to the safest studied dose per the manufacturer’s product insert; OR BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans.
    [Show full text]
  • Ring-Substituted Amphetamine Interactions with Neurotransmitter Receptor Binding Sites in Human Cortex
    208 NeuroscienceLetters, 95 (1988) 208-212 Elsevier Scientific Publishers Ireland Ltd. NSL O5736 Ring-substituted amphetamine interactions with neurotransmitter receptor binding sites in human cortex Pamela A. Pierce and Stephen J. Peroutka Deparmentsof Neurologyand Pharmacology, Stanford University Medical Center, StanJbrd,CA 94305 (U.S.A.) (Received 31 May 1988; Revised version received 11 August 1988; Accepted 12 August 1988) Key words.' Ring-substituted amphetamine; (_+)-3,4-Methylenedioxyamphetamine; ( +_)-3,4-Methylene- dioxyethamphetamine; (_+)-3,4-Methylenedioxymethamphetamine; Ecstasy; 4-Bromo-2,5- dimethoxyphenylisopropylamine binding site; Human cortical receptor The binding affinities of 3 ring-substituted amphetamine compounds were determined at 9 neurotrans- mitter binding sites in human cortex. (_+)-3,4-Methylenedioxyamphetamine (MDAk (_+)-3,4-methylene- dioxyethamphetamine (MDE), and (_+)-3,4-methylenedioxymethamphetamine (MDMA or 'Ecstasy') all display highest affinity (approximately 1 /tM) for the recently identified 'DOB binding site' labeled by ['TBr]R(-)4-bromo-2,5-dimethoxyphenylisopropylamine ([77Br]R(-)DOB). MDA displays moderate affinity (4-5/iM) for the 5-hydroxytryptaminetA (5-HTr^), 5-HT_D,and =,-adrenergic sites in human cor- tex. MDE and MDMA display lower affinity or are inactive at all other sites tested in the present study. These observations are discussed in relation to the novel psychoactive effects of the ring-substituted amphetamines. A series of ring-substituted amphetamine derivatives exist which are structurally related to both amphetamines and hallucinogens. However, drugs such as (+)-3,4- methylenedioxyamphetamine (MDA), (_+)-3,4-methylenedioxyethamphetamine (MDE), and (+)-3,4-methylenedioxymethamphetamine (MDMA or 'Ecstasy') ap- pear to produce unique psychoactive effects which are distinct from the effects of both amphetamines and hallucinogens [13, 15].
    [Show full text]
  • Stimulant and Related Medications: US Food and Drug
    Stimulant and Related Medications: U.S. Food and Drug Administration-Approved Indications and Dosages for Use in Adults The therapeutic dosing recommendations for stimulant and related medications are based on U.S. Food and Drug Administration (FDA)-approved product labeling. Nevertheless, the dosing regimen is adjusted according to a patient’s individual response to pharmacotherapy. The FDA-approved dosages and indications for the use of stimulant and related medications in adults are provided in this table. All medication doses listed are for oral administration. Information on the generic availability of the stimulant and related medications can be found by searching the Electronic Orange Book at https://www.accessdata.fda.gov/scripts/cder/ob/default.cfm on the FDA website. Generic Medication Indication Dosing Information Other Information Availability amphetamine/dextroamphetamine ADHD Initial dose: May increase daily dose by 5 mg at Yes mixed salts[1] 5 mg once or twice a day; weekly intervals until optimal response Maximum dose: 40 mg per day is achieved. Only in rare cases will it be necessary to exceed a total of 40 mg per day. amphetamine/dextroamphetamine narcolepsy Initial dose: 10 mg per day; May increase daily dose by 10 mg at Yes mixed salts Usual dose: weekly intervals until optimal response 5 mg to 60 mg per day is achieved. Take first dose in divided doses upon awakening. amphetamine/dextroamphetamine ADHD Recommended dose: Patients switching from regular-release Yes mixed salts ER*[2] 20 mg once a day amphetamine/dextroamphetamine mixed salts may take the same total daily dose once a day. armodafinil[3] narcolepsy Recommended dose: Take as a single dose in the morning.
    [Show full text]
  • What Every Clinician Should Know Before Starting a Patient on Meds
    CARING FOR CHILDREN WITH ADHD: A RESOURCE TOOLKIT FOR CLINICIANS, 2ND EDITION Basic Facts: What Every Clinician Should Know Before Starting a Patient on Medication Studies have shown that treatment for attention-deficit/ • If you reach the maximum recommended dose without • hyperactivity disorder (ADHD) with medication is effective in noticeable improvement in symptoms, try a different stimulant treating the symptoms of ADHD alone or in combination with medication class. Approximately 80% of children will respond to behavioral interventions. at least 1 of the 2 stimulant classes tried. • Stimulant medications also improve academic productivity but • When changing medications, be careful about the dose not cognitive abilities or academic skills. equivalence of different stimulant medication classes; in general, equivalent doses for dexmethylphenidate and Stimulants can help reduce oppositional, aggressive, impulsive, • amphetamine-based stimulants are approximately half of a and delinquent behaviors in some children. methylphenidate dose. Several types of medications are Food and Drug Administration Non-stimulant medications may require 2 or more weeks to see • (FDA)-approved for the treatment of ADHD. • effects, so you should titrate up more slowly than you would • Stimulant medications: methylphenidate, dexmethylphenidate, for stimulant medications. Obtaining follow-up rating scales is dextroamphetamine, mixed amphetamine salts, even more important than for stimulant medications because lisdexamfetamine changes are more gradual. • Non-stimulant medications: atomoxetine, and extended-release • Managing side effects effectively can improve adherence to and guanfacine and clonidine satisfaction with stimulant medications. When choosing which stimulant and dose to start first, consider • Common side effects to discuss with families include • stomachache, headache, decreased appetite, sleep problems, Family preference and experience with the medication, including • and behavioral rebound.
    [Show full text]
  • Differentially Affect Monoamine Transporters and Abuse Liability
    Neuropsychopharmacology (2017) 42, 1950–1961 © 2017 American College of Neuropsychopharmacology. All rights reserved 0893-133X/17 www.neuropsychopharmacology.org N-Alkylated Analogs of 4-Methylamphetamine (4-MA) Differentially Affect Monoamine Transporters and Abuse Liability Ernesto Solis Jr1, John S Partilla2, Farhana Sakloth3, Iwona Ruchala4, Kathryn L Schwienteck5, 4 4 3 5 *,2 Louis J De Felice , Jose M Eltit , Richard A Glennon , S Stevens Negus and Michael H Baumann 1In Vivo Electrophysiology Unit, Behavioral Neuroscience Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA; 2Designer Drug Research Unit, Intramural Research Program, National Institute on Drug Abuse, 3 National Institutes of Health, Baltimore, MD, USA; Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA, USA; 4 5 Department of Physiology and Biophysics, Virginia Commonwealth University, Richmond, VA, USA; Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA Clandestine chemists synthesize novel stimulant drugs by exploiting structural templates known to target monoamine transporters for dopamine, norepinephrine, and serotonin (DAT, NET, and SERT, respectively). 4-Methylamphetamine (4-MA) is an emerging drug of – abuse that interacts with transporters, but limited structure activity data are available for its analogs. Here we employed uptake and release assays in rat brain synaptosomes, voltage-clamp current measurements in cells expressing transporters, and calcium flux assays in cells coexpressing transporters and calcium channels to study the effects of increasing N-alkyl chain length of 4-MA on interactions at DAT, NET, and SERT. In addition, we performed intracranial self-stimulation in rats to understand how the chemical modifications affect abuse liability.
    [Show full text]
  • MDMA, MBDB' and I! I the Classichallucinogens
    Differences Between the Mechanism I t of Action of MDMA, MBDB' and i! I the ClassicHallucinogens. i Identification of a New Therapeutic Class: Entactogens Jawi'ri", ! 7 U$ DAVID E. NICHOLS, PH.D.* The widespread use of psychedelic drugs, such as quantitative structure-activity relationships (QSARs). lysergic ac;.d diethylamide (LSD), during the 1960's and Simply stated, attempts are made to find quantitative 1970's IcC to severe reactions by governmental agencies correlations (or equations) that relate biological activity to and proscriptions against their use. However, with the fundamental properties of the molecule. This approach is high deg _e of interest in mind-altering drugs in the being widely developed in the pharmaceutical industry in United States, as evidenced by their widespread popular- order to understand more fully how particular types of ity, it wasonlyamatteroftimebeforenewdrugsappeared drugs work, and to be able to predict which additional that were developed outside of the pharmaceutical corn- molecules should be synthesized. It should also be added panics, that no equations have been developed that adequately j Nearly 70 years after its first synthesis, 3,4- correlate hallucinogenic or psychedelic activity with any methy'enedioxymethamphetamine (MDMA) was redis- particular molecular property. covered. Although it had its' more recent origin in the class In this context, it is important to define clearly the of dr. gs that is generally defined as psychedelic or hallu- type of biological activity that is being measured. It is cino enic, it clearly appears different from LSD. In hu- typical that if a molecule has several different sites of mar , MDMA induces a state of reduced anxiety and action in the brain, that each oneof these actions may be lc .red defensiveness that makes it attractive to thera- related to entirely different structural features or proper- pi .
    [Show full text]
  • Recommended Methods for the Identification and Analysis Of
    Vienna International Centre, P.O. Box 500, 1400 Vienna, Austria Tel: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org RECOMMENDED METHODS FOR THE IDENTIFICATION AND ANALYSIS OF AMPHETAMINE, METHAMPHETAMINE AND THEIR RING-SUBSTITUTED ANALOGUES IN SEIZED MATERIALS (revised and updated) MANUAL FOR USE BY NATIONAL DRUG TESTING LABORATORIES Laboratory and Scientific Section United Nations Office on Drugs and Crime Vienna RECOMMENDED METHODS FOR THE IDENTIFICATION AND ANALYSIS OF AMPHETAMINE, METHAMPHETAMINE AND THEIR RING-SUBSTITUTED ANALOGUES IN SEIZED MATERIALS (revised and updated) MANUAL FOR USE BY NATIONAL DRUG TESTING LABORATORIES UNITED NATIONS New York, 2006 Note Mention of company names and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. ST/NAR/34 UNITED NATIONS PUBLICATION Sales No. E.06.XI.1 ISBN 92-1-148208-9 Acknowledgements UNODC’s Laboratory and Scientific Section wishes to express its thanks to the experts who participated in the Consultative Meeting on “The Review of Methods for the Identification and Analysis of Amphetamine-type Stimulants (ATS) and Their Ring-substituted Analogues in Seized Material” for their contribution to the contents of this manual. Ms. Rosa Alis Rodríguez, Laboratorio de Drogas y Sanidad de Baleares, Palma de Mallorca, Spain Dr. Hans Bergkvist, SKL—National Laboratory of Forensic Science, Linköping, Sweden Ms. Warank Boonchuay, Division of Narcotics Analysis, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand Dr. Rainer Dahlenburg, Bundeskriminalamt/KT34, Wiesbaden, Germany Mr. Adrian V. Kemmenoe, The Forensic Science Service, Birmingham Laboratory, Birmingham, United Kingdom Dr. Tohru Kishi, National Research Institute of Police Science, Chiba, Japan Dr.
    [Show full text]
  • Randomized Controlled Trial of Dexamphetamine Maintenance for the Treatment of Methamphetamine
    RESEARCH REPORT doi:10.1111/j.1360-0443.2009.02717.x Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependenceadd_2717 146..154 Marie Longo1, Wendy Wickes1, Matthew Smout1, Sonia Harrison1, Sharon Cahill1 & Jason M. White1,2 Pharmacotherapies Research Unit, Drug and Alcohol Services South Australia, Norwood, South Australia, Australia1 and Discipline of Pharmacology, University of Adelaide, Adelaide, South Australia, Australia2 ABSTRACT Aim To investigate the safety and efficacy of once-daily supervised oral administration of sustained-release dexam- phetamine in people dependent on methamphetamine. Design Randomized, double-blind, placebo-controlled trial. Participants Forty-nine methamphetamine-dependent drug users from Drug and Alcohol Services South Australia (DASSA) clinics. Intervention Participants were assigned randomly to receive up to 110 mg/day sustained- release dexamphetamine (n = 23) or placebo (n = 26) for a maximum of 12 weeks, with gradual reduction of the study medication over an additional 4 weeks. Medication was taken daily under pharmacist supervision. Measurements Primary outcome measures included treatment retention, measures of methamphetamine consump- tion (self-report and hair analysis), degree of methamphetamine dependence and severity of methamphetamine withdrawal. Hair samples were analysed for methamphetamine using liquid chromatography-mass spectrometry. Findings Treatment retention was significantly different between groups, with those who received dexamphetamine remaining in treatment for an average of 86.3 days compared with 48.6 days for those receiving placebo (P = 0.014). There were significant reductions in self-reported methamphetamine use between baseline and follow-up within each group (P < 0.0001), with a trend to a greater reduction among the dexamphetamine group (P = 0.086).
    [Show full text]